Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group.

To analyze the benefits and risks of three common treatments, we randomly assigned 179 patients with Graves' hyperthyroidism as follows: 60 patients, 20-34 yr of age (young adults), received antithyroid drugs for 18 months (medical) or subtotal thyroidectomy (surgical), and 119 patients, 35-55 yr of age (old adults), received medical, surgical, or radioiodine (iodine-131) treatment. The follow-up time was at least 48 months. Antithyroid drugs, surgery, or iodine-131 treatment normalized the mean serum hormone levels within 6 weeks. The risk of relapse was highest in the medically treated young and old adults (42% vs. 34%), followed by that in those treated with iodine-131 (21%) and that in the surgically treated young and old adults (3% vs 8%), respectively. Elevated TSH receptor antibodies at the end of medical therapy or increasing TSH receptor antibodies values after medical or surgical treatment increased the probability of relapse. Development or worsening of ophthalmopathy was not associated with relapse per se. Ninety percent of the subjects in all groups were satisfied with the treatment they received. No significant difference in sick-leave due to Graves' or other diseases was seen during the first 2 yr after initiation of therapy. The increased risk of ophthalmopathy in patients with high serum T3 levels, especially when treated with iodine-131, and the relatively high frequency of relapse after treatment with antithyroid drugs are important factors to consider when selecting therapy for Graves' disease.

[1]  H. Blomgren,et al.  Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? , 1994, European journal of endocrinology.

[2]  W. Alexander,et al.  A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. , 1993, The Journal of clinical endocrinology and metabolism.

[3]  J. Chigot,et al.  The surgical treatment of Graves' disease. , 1993, Surgery, gynecology & obstetrics.

[4]  A. Taube,et al.  Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. , 1992, The New England journal of medicine.

[5]  D. Glinoer,et al.  Differences and similarities in the treatment of diffuse goiter in Europe and the United States. , 2009, Experimental and clinical endocrinology.

[6]  H. Röher,et al.  Surgery for immunogenic hyperthyroidism. , 2009, Experimental and clinical endocrinology.

[7]  C. Feek,et al.  The management of Graves' disease in New Zealand: results of a national survey. , 1991, The New Zealand medical journal.

[8]  P. Lundberg,et al.  Thyroid disease in middle‐aged and elderly Swedish women: thyroid‐related hormones, thyroid dysfunction and goitre in relation to age and smoking , 1991, Journal of internal medicine.

[9]  S. Christensen,et al.  The incidence of recurrence and hypothyroidism following treatment with antithyroid drugs, surgery or radioiodine in all patients with thyrotoxicosis in Malmö during the period 1970–1974 , 1991, Journal of internal medicine.

[10]  F. Karlsson,et al.  Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. , 1990, Acta endocrinologica.

[11]  D. Glinoer,et al.  Current trends in the management of Graves' disease. , 1990, The Journal of clinical endocrinology and metabolism.

[12]  R. Fauchet,et al.  Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. , 1990, The Journal of clinical endocrinology and metabolism.

[13]  F. Karlsson,et al.  Importance of tsh receptor activation in the development of severe endocrine ophthalmopathy , 1989 .

[14]  S. Nagataki,et al.  The management of hyperthyroidism due to Graves' disease in Japan in 1988. The Japan Thyroid Association. , 1989, Endocrinologia japonica.

[15]  G. Lundell,et al.  Observations on progress periods in Graves' ophthalmopathy , 1989 .

[16]  P. Laurberg,et al.  The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. , 1987, Acta endocrinologica. Supplementum.

[17]  J. Orgiazzi.  Management of Graves' hyperthyroidism. , 1987, Endocrinology and metabolism clinics of North America.

[18]  T. Tötterman,et al.  Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. , 1987, The New England journal of medicine.

[19]  B. Wadman,et al.  Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease. , 1986, The Journal of clinical endocrinology and metabolism.

[20]  A. Guerrier,et al.  THYROID STIMULATING ANTIBODIES: AN AID TO THE STRATEGY OF TREATMENT OF GRAVES' DISEASE? , 1984, Clinical endocrinology.

[21]  E. Kaplan,et al.  Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. , 1984, The New England journal of medicine.

[22]  C. Hardisty,et al.  THE EFFECT OF RADIOIODINE AND ANTITHYROID DRUGS ON SERUM LONG ACTING THYROID STIMULATOR PROTECTOR (LATS‐P). A THREE YEAR PROSPECTIVE STUDY , 1984, Clinical endocrinology.

[23]  J. Romaldini,et al.  Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. , 1983, The Journal of clinical endocrinology and metabolism.

[24]  L. Holm.  Changing annual incidence of hypothyroidism after iodine-131 therapy for hyperthyroidism, 1951-1975. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  L. Holm,et al.  Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  D. Munro,et al.  THE PREDICTION OF RELAPSE AFTER DRUG TREATMENT OF GRAVES' DISEASE BY ASSAY OF LONG ACTING THYROID STIMULATOR‐PROTECTOR (LATS‐P) , 1981, Clinical endocrinology.

[27]  S. N. Madsen,et al.  INFLUENCE OF TREATMENT WITH RADIOIODINE AND PROPYLTHIORACIL ON THYROID STIMULATING IMMUNOGLOBULINS IN GRAVES' DISEASE , 1980 .

[28]  B. Smith,et al.  PREDICTION OF RELAPSE IN HYPERTHYROID GRAVES' DISEASE , 1980, The Lancet.

[29]  S. Nagataki,et al.  Thionamide therapy in Graves' disease: relation of relapse rate to duration of therapy. , 1980, Annals of internal medicine.

[30]  C. Teng,et al.  Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study. , 1980, The Journal of clinical endocrinology and metabolism.

[31]  D. Sugrue,et al.  Hyperthyroidism in the land of Graves: results of treatment by surgery, radio-iodine and carbimazole in 837 cases. , 1980, The Quarterly journal of medicine.

[32]  A. McGregor,et al.  EFFECTS OF RADIOIODINE ON THYROTROPHIN BINDING INHIBITING IMMUNOGLOBULINS IN GRAVES’DISEASE , 1979, Clinical endocrinology.

[33]  D. Appleton,et al.  THE SPECTRUM OF THYROID DISEASE IN A COMMUNITY: THE WHICKHAM SURVEY , 1977, Clinical endocrinology.

[34]  D. C. Evered,et al.  VALUE OF THYROID-STIMULATING-ANTIBODY DETERMINATIONS IN PREDICTING SHORT-TERM THYROTOXIC RELAPSE IN GRAVES' DISEASE , 1977, The Lancet.

[35]  Douglas Jg.  The Vanderbilt experience with I 131 treatment for Graves' disease. , 1973 .

[36]  J. Glennon,et al.  Hypothyroidism after low-dose 131 I treatment of hyperthyroidism. , 1972, Annals of internal medicine.

[37]  W. Beierwaltes,et al.  Treatment of hyperthyroidism with sodium iodide I-131. , 1966, JAMA.

[38]  Larsson Lg.  Studies on radioiodine treatment of thyrotoxicosis; with special reference to the behaviour of the radioiodine tracer tests. , 1955 .